NASDAQ:ACLX 9 December 2025 - 25 February 2026

Gilead agreed to acquire Arcellx for $115 per share in cash plus a $5 contingent payout tied to anito-cel sales. Arcellx closed flat at $113.75 Tuesday, just below the offer price, and traded at $113.70 after hours. The tender offer remains subject to antitrust review and FDA approval, with a PDUFA date set for Dec. 23, 2026. Gilead shares slipped 1% on the day.

Arcellx shares traded at $113.86 Tuesday after Gilead Sciences agreed to buy the company for $115 per share in cash plus a $5 contingent value right tied to anito-cel sales. The $7.8 billion deal awaits a tender offer launch and regulatory approvals, with the FDA’s decision on anito-cel expected by December 23, 2026.

Arcellx shares jumped 77.6% to $113.84 after Gilead Sciences agreed to buy the company for $115 per share in cash plus a contingent value right tied to anito-cel sales. The deal came as U.S. stocks fell on new 15% global tariffs announced by President Trump. Gilead shares slipped 0.6%. Investors are watching the FDA’s Dec. 23, 2026 review deadline for anito-cel, a CAR-T therapy for multiple myeloma.